Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.
|Articles|June 1, 2019
- BioPharm International-06-01-2019
- Volume 43
- Issue 6
BioPharm International, June 2019 Issue (PDF)
Click the title above to open the BioPharm International June 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
FDA Advances New Approach to Drug Quality Assessmentover 7 years ago
Bio/Pharma Facilities Still Have a Lot to Learnover 7 years ago
Moving PAT from Concept to Realityover 7 years ago
Streamlining Upstream Processing: A Good Place to Startover 7 years ago
On the Right Trackover 7 years ago
Quality Agreements and Out-of-Specification Investigationsover 7 years ago
Addressing the Complex Nature of Downstream Processing with QbDover 7 years ago
From Data to InformationAdvertisement
Related to this article
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Inebilizumab (Uplizna) cut MG-ADL scores by 1.9 points versus placebo, supporting its approval in Japan for myasthenia gravis.
Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
Today’s biopharma news highlights GSK’s myeloma strategy, Insilico’s AI longevity research, and innovations that may improve future treatment outcomes.
As data volumes explode, clinical data harmonization, hybrid cloud, and AI are reshaping biopharma IT into the industry's core growth engine.
Advertisement
Advertisement